Induction chemoradiotherapy for esophageal cancer: Comparing CROSS regimen with cisplatin/5-FU.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.4070
Abstract: 4070Background: While trimodal therapy with neoadjuvant carboplatin/paclitaxel (CP) has demonstrated superiority over surgery alone for treatment of locally advanced esophageal cancer (LAEC), its superiority to alternative regimens is yet unproven. Here we directly compare CP… read more here.
Keywords: esophageal cancer; esophageal; chemoradiotherapy esophageal; induction chemoradiotherapy ... See more keywords
Induction chemoradiotherapy versus induction chemotherapy for potentially resectable stage IIIA (N2) non-small cell lung cancer: a systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of thoracic disease"
DOI: 10.21037/jtd.2018.04.24
Abstract: Background Non-small cell lung cancer (NSCLC) accounts for 85% to 90% of lung cancer cases. At diagnosis, around 30% of NSCLC patients are already at stage IIIA (N2). One standard treatment for this stage is… read more here.
Keywords: induction chemoradiotherapy; induction; stage iiia; induction chemotherapy ... See more keywords